Regulus Therapeutics Inc RGLS:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 10:39 AM EDT
2.16quote price arrow down-0.06 (-2.70%)
Volume
66,036
52 week range
1.08 - 3.79
Loading...
  • Open2.23
  • Day High2.31
  • Day Low2.15
  • Prev Close2.22
  • 52 Week High3.79
  • 52 Week High Date03/12/24
  • 52 Week Low1.08
  • 52 Week Low Date01/17/24

Key Stats

  • Market Cap141.405M
  • Shares Out65.47M
  • 10 Day Average Volume0.31M
  • Dividend-
  • Dividend Yield-
  • Beta1.60
  • YTD % Change71.09

KEY STATS

  • Open2.23
  • Day High2.31
  • Day Low2.15
  • Prev Close2.22
  • 52 Week High3.79
  • 52 Week High Date03/12/24
  • 52 Week Low1.08
  • 52 Week Low Date01/17/24
  • Market Cap141.405M
  • Shares Out65.47M
  • 10 Day Average Volume0.31M
  • Dividend-
  • Dividend Yield-
  • Beta1.60
  • YTD % Change71.09

RATIOS/PROFITABILITY

  • EPS (TTM)-1.58
  • P/E (TTM)-1.36
  • Fwd P/E (NTM)-2.54
  • EBITDA (TTM)-30.882M
  • ROE (TTM)-110.29%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-439.94%
  • Debt To Equity (MRQ)6.30%

EVENTS

  • Earnings Date05/09/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Regulus Therapeutics Inc

 

Profile

MORE
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant...
Stelios Papadopoulos Ph.D.
Independent Chairman of the Board
Joseph Hagan
Chief Executive Officer, Director
Preston Klassen M.D.
President, Head of Research & Development, Director
Cris Calsada CPA
Chief Financial Officer
Address
SUITE 210, 3545 JOHN HOPKINS COURT
San Diego, CA
92121
United States

Top Peers

SYMBOLLASTCHG%CHG
INO
Inovio Pharmaceuticals Inc
9.80-0.40-3.92%
INMB
INmune Bio Inc
8.75-0.05-0.57%
ACET
Adicet Bio Inc
1.91-0.11-5.58%
LENZ
LENZ Therapeutics Inc
17.14-0.35-2.00%
CADL
Candel Therapeutics Inc
5.45-0.01-0.18%